14 documents found, page 1 of 2

In Vitro CRISPR/Cas9 Transfection and Gene-Editing Mediated by Multivalent Cati...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated nuclease 9 (Cas9) gene-editing offers exciting new therapeutic possibilities for disease treatment with a genetic etiology such as cancer, cardiovascular, neuronal, and immune disorders. However, its clinical translation is being hampered by the lack of safe, versatile, and effective nonviral delivery systems. Herein we rep...

In vitro selection of DNA aptamers against human osteosarcoma

Background. Osteosarcoma is a highly malignant bone tumor, most frequently occurring in the rapid bone growth phase. Effective treatment of this disease is hindered by the lack of specific probes for early diagnosis and the fast cancer widespread. Methods. To find such probes, the cell-Systematic Evolution of Ligands by EXponential enrichment (cell-SELEX) methodology was implemented against the human osteosarco...

Non-viral delivery of CRISPR/Cas9 DNA for gene editing via multivalent cationic...

[Excerpt] Introduction: CRISPR/Cas9 gene editing technology has revolutionized medical research by opening new therapeutic possibilities for disease treatment such as cancer, cardiovascular, neuronal and immune disorders [1]. Even with the emergence of this technology, the lack of clinically viable delivery systems continues to hinder CRISPR therapeutic applications. Viral vectors have been sucessfully used for...

Identification of novel aptamers targeting cathepsin B-overexpressing prostate ...

Increased levels of cathepsin B (CatB), a cysteine protease, have been associated with different types of tumors, including prostate cancer. Hence, the identification of novel targeting ligands homing CatB may be a promising approach for the development of CatB-targeted therapies. In this work, a methodology called systematic evolution of ligands by EXponential enrichment (SELEX) was used to generate and isolat...

Development of targeted delivery platforms against highly metastatic cancers

O cancro é uma das principais causas de morbidade e mortalidade a nível mundial, e as suas metástases são responsáveis por cerca de 90% das mortes. As atuais abordagens terapêuticas têm baixas taxas de sucesso em casos de doença metastática e a maioria dos pacientes não pode ser curada. Portanto, é crucial encontrar novas estratégias para desenvolver terapias eficientes dirigidas ao alvo. As tecnologias baseada...

Cellular delivery of CRISPR/Cas9 plasmid using multivalent cationic liposomes

[Excerpt] Background: Gene therapy techniques have been aimed at mitigating disease features of recessive and dominant disorders, as well as several cancers, cardiovascular, neuronal and immune diseases [1]. In recent years, the clustered regularly interspaced short palindromic repeats (CRISPR) and Cas9 protein system has been gaining recognition as a revolutionary tool for gene therapy. However, the implementa...

Selection of aptamers against triple negative breast cancer cells using high th...

Triple-negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands is essential to develop novel targeted therapies. In this study, we aimed to identify new aptamers that bind to highly metastatic breast cancer MDA-MB-231 cells using the cell-SELEX technology aided by high throughput...

Targeting oncogenic microRNAs in triple negative breast cancer using a CRISPR/C...

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Lack of effective targeted therapies, significant genetic heterogeneity and poor response to conventional chemotherapies are the major reasons contributing to poor prognosis and highly mortality rates. Given to emerging findings, oncogenic microRNAs (miRNAs) are proving to be useful potential therapeutics in different types of...

In silico prediction and design of CRISPR sgRNAs targeting miR-155 for TNBC tre...

CRISPR/Cas9-mediated knockout of miR-155 for Triple Negative Breast Cancer trea...

Introduction Triple Negative Breast Cancer (TNBC) is the most aggressive breast cancer subtype. Lack of effective targeted therapies, significant genetic heterogeneity and poor response to conventional chemotherapies are the major reasons contributing to poor prognosis and high mortality rates. A subset of microRNAs (miRNAs) has been documented as oncogenic miRNAs (oncomiRs) because they have an important role ...